Aditxt, Inc. (ADTX)
NASDAQ: ADTX · Real-Time Price · USD
0.4754
-0.0294 (-5.82%)
At close: Oct 14, 2025, 4:00 PM EDT
0.4630
-0.0124 (-2.61%)
Pre-market: Oct 15, 2025, 7:47 AM EDT
Aditxt Revenue
Aditxt had revenue of $1.00K in the quarter ending June 30, 2025, a decrease of -97.73%. This brings the company's revenue in the last twelve months to $12.05K, down -96.35% year-over-year. In the year 2024, Aditxt had annual revenue of $133.99K, down -79.23%.
Revenue (ttm)
$12.05K
Revenue Growth
-96.35%
P/S Ratio
28.13
Revenue / Employee
$464
Employees
26
Market Cap
2.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 133.99K | -511.19K | -79.23% |
| Dec 31, 2023 | 645.18K | -288.54K | -30.90% |
| Dec 31, 2022 | 933.72K | 828.68K | 788.96% |
| Dec 31, 2021 | 105.03K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ADTX News
- 4 weeks ago - Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms - PRNewsWire
- 5 weeks ago - Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting - PRNewsWire
- 7 weeks ago - Aditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030 - Business Wire
- 7 weeks ago - Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law - PRNewsWire
- 2 months ago - FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis - PRNewsWire
- 2 months ago - Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update - PRNewsWire
- 2 months ago - Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative - Business Wire
- 2 months ago - Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference - PRNewsWire